Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer

Basel, November 1, 2016 - Novartis announced today that the US Food and Drug Administration (FDA) accepted the company ' s New Drug Application (NDA) for filing and granted Priority Review for LEE011 (ribociclib) as first-line treatment of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials